Avidity Biosciences End Period Cash Flow Over Time
| RNA Stock | USD 31.82 0.77 2.48% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Avidity Biosciences Performance and Avidity Biosciences Correlation. Avidity |
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Avidity Biosciences. If investors know Avidity will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Avidity Biosciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (2.88) | Revenue Per Share 0.103 | Quarterly Revenue Growth (0.17) | Return On Assets (0.18) | Return On Equity (0.28) |
The market value of Avidity Biosciences is measured differently than its book value, which is the value of Avidity that is recorded on the company's balance sheet. Investors also form their own opinion of Avidity Biosciences' value that differs from its market value or its book value, called intrinsic value, which is Avidity Biosciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Avidity Biosciences' market value can be influenced by many factors that don't directly affect Avidity Biosciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Avidity Biosciences' value and its price as these two are different measures arrived at by different means. Investors typically determine if Avidity Biosciences is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Avidity Biosciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.
Cross Equities End Period Cash Flow Analysis
Compare Avidity Biosciences and related stocks such as Tcr2 Therapeutics, Revolution Medicines, and Black Diamond Therap End Period Cash Flow Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RVMD | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 9.1 M | 69.8 M | 16.9 M | 105.4 M | 110.2 M | 163.1 M | 699.2 M | 734.1 M |
| BDTX | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 7.9 M | 51.7 M | 154.7 M | 35.8 M | 67 M | 35.5 M | 57 M | 64.4 M |
| PASG | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 24.9 M | 158.9 M | 135 M | 129 M | 34.6 M | 21.7 M | 20.6 M |
| AKRO | 598 K | 598 K | 598 K | 598 K | 598 K | 598 K | 598 K | 598 K | 76 M | 64.8 M | 187.4 M | 150.6 M | 249.9 M | 234.2 M | 151.4 M |
| PTGX | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 9.3 M | 4.1 M | 21.1 M | 106.5 M | 82.7 M | 33.5 M | 117.8 M | 123.9 M | 126 M | 187 M | 196.3 M |
| STOK | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 1.9 M | 105.6 M | 222.7 M | 287.5 M | 145.5 M | 114.1 M | 192 M | 168 M |
| IGMS | 482 K | 482 K | 482 K | 482 K | 482 K | 482 K | 482 K | 482 K | 2 M | 35.9 M | 241.1 M | 134 M | 121.9 M | 113.1 M | 101.9 M |
| CGEM | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 47.7 M | 33.8 M | 33.8 M | 63.2 M | 168.2 M | 59.8 M | 156.2 M | 98.4 M | 98.6 M |
| MLYS | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 1.4 M | 10.7 M | 87.7 M | 49.3 M | 41 M |
| DAWN | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 27.3 M | 43.7 M | 284.3 M | 85.3 M | 230.8 M | 147.7 M |
| SWTX | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 10.3 M | 45.6 M | 328.2 M | 147.7 M | 104.5 M | 68.1 M | 176.7 M | 138.4 M |
| RLAY | 422.4 M | 422.4 M | 422.4 M | 422.4 M | 422.4 M | 422.4 M | 422.4 M | 422.4 M | 422.4 M | 42.8 M | 448.5 M | 282.7 M | 154.4 M | 146.4 M | 199.6 M |
| PLRX | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 4.3 M | 60.9 M | 85.8 M | 50.9 M | 51.7 M | 33.7 M | 64.7 M | 55.3 M |
| ARVN | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 5.1 M | 30.9 M | 3.2 M | 9.2 M | 588.4 M | 112.8 M | 86.8 M | 317.2 M | 158.6 M |
Avidity Biosciences and related stocks such as Tcr2 Therapeutics, Revolution Medicines, and Black Diamond Therap End Period Cash Flow description
My Equities
My Current Equities and Potential Positions
| Avidity Biosciences | RNA |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Location | California; U.S.A |
| Exchange | NASDAQ Exchange |
USD 31.82
Check out Avidity Biosciences Performance and Avidity Biosciences Correlation. For information on how to trade Avidity Stock refer to our How to Trade Avidity Stock guide.You can also try the Efficient Frontier module to plot and analyze your portfolio and positions against risk-return landscape of the market..
Avidity Biosciences technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.